Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amgen has announced results from preclinical studies suggesting a significantly greater reduction in tumor growth when AMG 386 was combined with either of bevacizumab or motesanib diphosphate, compared with either treatment alone.
Subscribe to our email newsletter
The data were generated from three blinded studies of preclinical models of colon carcinoma randomized into three experimental groups. The models were treated with suboptimal doses of motesanib diphosphate (37.5–75 milligrams per kg QD, PO), bevacizumab (2.8 micrograms twice per week), AMG 386 (2.8-14 micrograms twice per week) or combinations thereof.
Roger Perlmutter, Amgen’s executive vice president of R&D, said: “What’s encouraging about these early results is that they indicate that blocking more than one angiogenesis pathway may offer enhanced potential to inhibit tumor growth. We look forward to investigating this finding further.”